- Home
- CAL vs AUPH Comparison
CAL vs AUPH Comparison
Compare CAL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAL | AUPH |
|---|---|---|
| Founded | 1878 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.1M | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | CAL | AUPH |
|---|---|---|
| Price | $13.82 | $15.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $14.00 | ★ $17.25 |
| AVG Volume (30 Days) | 968.5K | ★ 1.0M |
| Earning Date | 12-09-2025 | 02-26-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | 0.55 |
| Revenue | ★ $2,702,018,000.00 | $265,808,000.00 |
| Revenue This Year | $2.22 | $21.76 |
| Revenue Next Year | $3.67 | $16.45 |
| P/E Ratio | ★ $20.71 | $29.12 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $9.54 | $6.55 |
| 52 Week High | $22.61 | $16.54 |
Technical Indicators
Market Signals| Indicator | CAL | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 46.12 |
| Support Level | $11.94 | $14.82 |
| Resistance Level | $13.42 | $15.98 |
| Average True Range (ATR) | 0.64 | 0.47 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 80.44 | 30.81 |
Price Performance
Historical ComparisonAbout CAL Caleres Inc.
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.